Japanese Red Cross Medical Center
In research, Japanese Red Cross Medical Center stands highest in Medicine (#8,888 of 10,443 worldwide) and Health Sciences (#10,539 of 11,982 worldwide), 2022–2025. Relative to its size it is most specialised in Pulmonary and Respiratory Medicine — Pulmonary and Respiratory Medicine is 8.8× its share of world research.
- World rank, 2022–2025
- #23,790 of 28,054 · #21,954 all time
- Rank in Japan
- #774 of 1,070
- Research works
- 1.3k ▲ 5% vs 2013–17
- Citations
- 22k 17.1 per fractional work
- Top-10% rate
- 5.3% record average 16.5%
- Open access
- 41% world 28%
What is Japanese Red Cross Medical Center known for in research?
The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works | All time |
|---|---|---|---|---|---|
| MedicineField | #8,888 of 10,443 | 5.2% | 134 | #6325 | |
| Health SciencesDomain | #10,539 of 11,982 | 5.2% | 139 | #8334 |
Each strip is that field’s whole ranked pool, with the notch where Japanese Red Cross Medical Center sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
What does Japanese Red Cross Medical Center specialise in?
Where its research is concentrated relative to its size: Pulmonary and Respiratory Medicine takes 8.8× the share of its output that it takes of world research.
- Pulmonary and Respiratory MedicineSubfield · 22.1 works8.8×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 4.3×. Every wedge is a field page.
- Medicine 4.3×
- Biochemistry, Genetics and Molecular Biology 1.6×
- Nursing 1.2×
- Immunology and Microbiology 1.1×
- Neuroscience 0.9×
- Health Professions 0.8×
- Psychology 0.5×
- Pharmacology, Toxicology and Pharmaceutics 0.4×
- Dentistry 0.2×
- Economics, Econometrics and Finance 0.2×
- Agricultural and Biological Sciences 0.1×
- Arts and Humanities 0.1×
- Physics and Astronomy 0.1×
- Chemistry 0.1×
- Engineering 0.0×
- Computer Science 0.0×
- Social Sciences 0.0×
- Environmental Science 0.0×
- Materials Science 0.0×
- Mathematics 0.0×
Who are the top researchers at Japanese Red Cross Medical Center?
Ranked on the composite score, Shingo Miyamoto, Masaharu Inoue and Tomisaku Kawasaki lead among researchers whose main affiliation is Japanese Red Cross Medical Center.
- 1 Shingo Miyamoto Japan · #61,099 worldwide 240 citations · 54 works
- 2 Masaharu Inoue Japan · #111,466 worldwide 195 citations · 44 works
- 3 Tomisaku Kawasaki Japan · #188,915 worldwide 128 citations · 21 works
- 4 Hideo Kunitoh Japan · #311,327 worldwide 92 citations · 47 works
- 5 Tadao Ishida Japan · #346,279 worldwide 120 citations · 45 works
- 6 Tamiko Takemura Japan · #461,987 worldwide 183 citations · 104 works
- 7 Ichirō Suzuki Japan · #557,772 worldwide 218 citations · 95 works
- 8 Manabu Sakuta Japan · #640,370 worldwide 27 citations · 19 works
- 9 Kohei Takada Japan · #670,711 worldwide 43 citations · 35 works
- 10 Minoru Inomata Japan · #717,521 worldwide 38 citations · 22 works
Which keywords describe research at Japanese Red Cross Medical Center?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Proteasome Inhibitors, Staging System, Minimal Residual Disease, Diagnosis Criteria, International Myeloma Working Group, Diagnosis, Immunotherapy and Epidemiology.
- Tumor Regression
- Surgical Treatment
- EGFR Mutations
- Immunosuppression
- Taxanes
- Metastatic Breast Cancer
- Neurotoxicity
- Epithelial-Mesenchymal Transition
- Prognosis
- Spinal Fusion
- Treatment Guidelines
- Clinical Trials
- Radiotherapy
- Prognostic Factors
- Targeted Therapy
- Chemotherapy
- Treatment
- Minimal Residual Disease
- Diagnosis Criteria
- Proteasome Inhibitors
- Epidemiology
- Staging System
- International Myeloma Working Group
- Diagnosis
- Immunotherapy
- Quality of Life
- Management
- Clinical Practice Guidelines
- Risk Factors
- Surgical Management
- Fibrosis
- Degenerative Disc Disease
- Interstitial Lung Disease
- Idiopathic Pulmonary Fibrosis
- TGF-ß
- Chemotherapy-Induced Peripheral Neuropathy
- Clinical Outcomes
- ALK Inhibitors
- Lymphoma
- Adjuvant Therapy
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology15▲ 2.3×67 topics
- Proteasome Inhibitors14▲ 118×2 topics
- Staging System14▲ 135×2 topics
- Diagnosis Criteria13▲ 232×1 topic
- International Myeloma Working Group13▲ 232×1 topic
- Minimal Residual Disease13▲ 120×2 topics
- Diagnosis10▲ 6.8×27 topics
- Treatment10▲ 4.9×27 topics
- Immunotherapy9▲ 7.4×14 topics
- Chemotherapy8▲ 7.3×16 topics
- Quality of Life7▲ 2.9×15 topics
- Targeted Therapy6▲ 18×5 topics
- Management6▲ 4.9×20 topics
- Prognostic Factors6▲ 8.9×13 topics
- Clinical Practice Guidelines6▲ 6.7×11 topics
- Radiotherapy6▲ 8.8×10 topics
- Risk Factors6▲ 3.1×16 topics
- Clinical Trials5▲ 4.6×7 topics
- Surgical Management5▲ 7.3×14 topics
- Treatment Guidelines5▲ 14×4 topics
- Fibrosis5▲ 15×3 topics
- Spinal Fusion4▲ 29×2 topics
- Degenerative Disc Disease4▲ 28×2 topics
- Prognosis4▲ 8.1×7 topics
- Interstitial Lung Disease4▲ 40×2 topics
- Epithelial-Mesenchymal Transition4▲ 26×2 topics
- Idiopathic Pulmonary Fibrosis4▲ 53×1 topic
- Neurotoxicity4▲ 20×2 topics
- TGF-ß4▲ 16×1 topic
- Metastatic Breast Cancer4▲ 41×2 topics
- Chemotherapy-Induced Peripheral Neuropathy4▲ 71×1 topic
- Taxanes4▲ 71×1 topic
- Clinical Outcomes4▲ 10×4 topics
- Immunosuppression4▲ 24×3 topics
- ALK Inhibitors3▲ 33×1 topic
- EGFR Mutations3▲ 33×1 topic
- Lymphoma3▲ 12×3 topics
- Surgical Treatment3▲ 9.5×4 topics
- Adjuvant Therapy3▲ 15×2 topics
- Tumor Regression3▲ 17×2 topics
Which research topics does Japanese Red Cross Medical Center publish most on?
By volume in 2022–2025: Multiple Myeloma Research and Treatments, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Cancer Treatment and Pharmacology and Lung Cancer Treatments and Mutations.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Multiple Myeloma Research and Treatments Hematology 13 works
- 2 Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Pulmonary and Respiratory Medicine 4 works
- 3 Cancer Treatment and Pharmacology Oncology 4 works
- 4 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 3 works
- 5 Spine and Intervertebral Disc Pathology Pathology and Forensic Medicine 3 works
- 6 CAR-T cell therapy research Oncology 3 works
- 7 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 2 works
- 8 Protein Degradation and Inhibitors Molecular Biology 2 works
- 9 Peptidase Inhibition and Analysis Oncology 2 works
- 10 Cytomegalovirus and herpesvirus research Epidemiology 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Japanese Red Cross Medical Center's research output changed?
Output in 2018–2022 was 5% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Tokyo
- The University of Tokyo
- Tokyo Institute of Technology
- Keio University
- Waseda University
- Tokyo University of Science
- Nihon University
- Hitachi (Japan)
- NTT (Japan)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.